How should I draw and administer a 110‑milligram dose of enoxaparin from a 120‑milligram/0.8‑milliliter vial?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: February 25, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Drawing and Administering 110 mg Enoxaparin from a 120 mg/0.8 mL Vial

To administer 110 mg from a 120 mg/0.8 mL vial, draw 0.73 mL using a standard 1 mL syringe and administer subcutaneously.

Calculation Method

  • The concentration of your vial is 150 mg/mL (120 mg ÷ 0.8 mL = 150 mg/mL) 1
  • To deliver 110 mg: divide 110 mg by 150 mg/mL = 0.73 mL 1
  • Use a standard 1 mL syringe graduated in 0.01 mL increments for accurate measurement 2

Step-by-Step Administration Protocol

Drawing the Dose

  • Remove the protective cap from the prefilled syringe or vial 1
  • Draw exactly 0.73 mL into a 1 mL syringe (this equals 110 mg) 2
  • Expel any air bubbles by tapping the syringe gently and pushing the plunger to the 0.73 mL mark 1
  • Verify the volume is precisely at 0.73 mL before proceeding 2

Subcutaneous Injection Technique

  • Select an injection site on the left or right anterolateral or posterolateral abdominal wall 1
  • Do not inject into muscle tissue—enoxaparin must be given subcutaneously 1
  • Pinch a fold of skin between thumb and forefinger 1
  • Insert the entire length of the needle at a 90-degree angle into the skin fold 1
  • Inject the full dose without aspirating 1
  • Hold the skin fold throughout the injection and for 10 seconds after withdrawal 1
  • Do not rub the injection site, as this increases bruising risk 1

Critical Safety Considerations

  • Renal function check is mandatory: if creatinine clearance is <30 mL/min, the dose must be reduced to 1 mg/kg once daily instead of twice daily 3, 1
  • For patients ≥75 years receiving this dose for acute coronary syndrome with fibrinolysis, the maximum dose should not exceed 75 mg per injection 3, 1
  • Never switch between enoxaparin and unfractionated heparin once treatment is initiated, as this substantially increases bleeding risk 4, 3
  • If the patient weighs <50 kg, consider anti-Xa monitoring due to increased bleeding risk with standard weight-based dosing 1

Common Pitfalls to Avoid

  • Do not round to 0.7 mL or 0.75 mL—use the precise 0.73 mL calculation to avoid under- or over-dosing 2
  • Avoid intramuscular injection, which can cause hematoma formation 1
  • Do not administer within 10–12 hours of neuraxial anesthesia or epidural catheter removal 3, 1
  • Never use insulin syringes for doses requiring decimal precision in adults—use a standard 1 mL syringe with 0.01 mL graduations 2

References

Guideline

Enoxaparin Dosing and Administration for DVT Prophylaxis and Stroke Prevention

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2026

Guideline

Timing of Clexane Initiation in ICU Patients

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2026

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Related Questions

How is the dose of Lovenox (enoxaparin) calculated?
What is the dosing for Lovenox (enoxaparin)?
What is the typical bridging dose regimen for Enoxaparin (low molecular weight heparin)?
What is the best approach to transition a patient with a history of myocardial infarction (MI) from Lovenox (enoxaparin) injections to an alternative anticoagulant?
What are the loading and maintenance doses for enoxaparin (low molecular weight heparin)?
Is amoxicillin monotherapy appropriate for treating an Enterobacter bugandensis infection?
In a pregnant woman with rheumatic mitral stenosis (mitral valve area <1.5 cm², New York Heart Association functional class III‑IV despite optimal medical therapy), what are the indications, technique, contraindications, potential complications, and post‑procedure management for a transfemoral balloon mitral valvotomy?
How should chronic constipation be managed in a middle‑aged adult?
I have kaleidoscopic vision—what are the likely causes (e.g., migraine aura, retinal detachment, occipital seizure, drug‑induced disturbance) and what immediate evaluation and management steps should I take?
Is pitavastatin suitable as first‑line therapy to lower low‑density lipoprotein cholesterol (LDL‑C) and modestly increase high‑density lipoprotein cholesterol (HDL‑C) in a patient with dyslipidaemia who has diabetes mellitus or is at high risk for type 2 diabetes, and does it adversely affect glycaemic control?
What is the recommended gabapentin dose, titration schedule, and treatment duration for an adult over 50 with acute herpes zoster‑associated neuropathic pain, including adjustments for renal impairment and use with antiviral therapy?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.